New Benzothiazole/thiazole-Containing Hydroxamic Acids as Potent Histone Deacetylase Inhibitors and Antitumor Agents

Author(s): Truong Thanh Tung, Dao Thi Kim Oanh, Phan Thi Phuong Dung, Van Thi My Hue, Sang Ho Park, Byung Woo Han, Youngsoo Kim, Jin-Tae Hong, Sang-Bae Han, Nguyen-Hai Nam

Journal Name: Medicinal Chemistry

Volume 9 , Issue 8 , 2013

Become EABM
Become Reviewer
Call for Editor


Results from clinical studies have demonstrated that inhibitors of histone deacetylase (HDAC) enzymes possess promise for the treatment of several types of cancer. Zolinza® (widely known as SAHA) has been approved by the FDA for the treatment of T-cell lymphoma. As a continuity of our ongoing research to find novel small molecules to target these important enzymes, we synthesized a series of benzothiazole-containing analogues of SAHA and found several compounds with very potent anticancer cytotoxicity. In this study, three more compounds of this type, including N1-(6- chlorobenzo[d]thiazol-2-yl)-N8-hydroxyoctanediamide (3a), N1-[6-(trifluoromethyl)benzo[d]thiazol-2-yl]-N8-hydroxyoctanediamide (3b) and N1-(thiazol-2-yl)-N8-hydroxyoctanediamide (6) were synthesized and evaluated for HDAC inhibition and cytotoxic activities. All three compounds showed very potent HDAC inhibitory effects. Docking revealed that both two compounds 3a, 3b showed higher affinities towards HDAC8 compared to SAHA. In vitro, compound 3a exhibited cytotoxicity equipotent to SAHA against five human cancer cell lines. In term of in vivo activity, compound 3a demonstrated equivalent efficacy to SAHA in mouse xenograft model.

Keywords: Histone deacetylase inhibitors, benzothiazole, heterocycle.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [1051 - 1057]
Pages: 7
DOI: 10.2174/15734064113099990027
Price: $65

Article Metrics

PDF: 92